PRISM will be accepting submissions for our next screen July 8 – July 26!

DMSO-soluble small molecules (single agent and combination format), and single agent antibodies, ADCs, and growth-inhibiting cytokines will be accepted for our 930 cancer cell line screen.

Consortium-style screens

We are accepting test agents for our next screen January 16 – February 2, 2024. Contact our team for more information on how to submit. PRISM invites collaborators to submit test agents to three consortium-style screens each year. These screens use the standard PRISM study design: 5-day assay, test agents run at 7 pt. dose for […]

Industrial collaborative working model

PRISM’s mission is to help improve cancer patients’ lives. To that end, we are excited to collaborate with industry partners to advance their understanding of their cancer therapeutics. Our working model for industry partners is that of a scientific collaboration to further cancer research. Some key points of our collaboration agreement include: Data Ownership – […]

PRISM’s high-throughput drug sensitivity assay

Traditional phenotypic screening is done one cell line at a time, requiring lots of time and reagents, which can slow down drug discovery and development efforts. PRISM’s unique approach to barcoding and pooling cell lines for high-throughput screening overcomes the limitations of single cell line studies, helping researchers rapidly collect cancer cell line drug-sensitivity data […]

Overview

The Broad Institute has made PRISM available to all collaborators. We are excited to collaborate with you to advance your research to find new treatments for cancer patients. Together we can provide a better understanding of cancer therapeutics and accelerate the drug discovery process. We are accepting test agents for our next screen January 16 […]